Search

for
Search:

GlossarySustained Drug Release

Sustained drug release refers to a method of delivering medication over an extended period, allowing for a gradual release of the active ingredient into the bloodstream. In the context of hair loss treatments, this approach can enhance the effectiveness of topical or systemic therapies by maintaining consistent drug levels, potentially improving outcomes in conditions like androgenetic alopecia. Key distinguishing characteristics include the formulation of the drug, which may involve polymers or other materials that control the rate of release, and the ability to reduce the frequency of dosing, thereby improving patient compliance.

Related Terms

Research

5 / 1000+ results

research Novel tip-loaded dissolving and implantable microneedle array patches for sustained release of finasteride

23 citations , July 2021 in “International Journal of Pharmaceutics”

New dissolving and implantable microneedle patches have been created for a long-lasting, non-invasive delivery of the drug finasteride.

research Dissolving microneedle array patches containing mesoporous silica nanoparticles of different pore sizes as a tunable sustained release platform

7 citations , December 2024 in “International Journal of Pharmaceutics”

Dissolving microneedle patches can effectively deliver drugs over time.

research Preparation and Properties of PVA/ZIF‐8 Sustained‐Release Fiber Loaded With Minoxidil Sulfate

January 2026 in “Journal of Applied Polymer Science”

The new fiber offers long-lasting minoxidil release and can be used in wigs for hair treatment and coverage.

research Dissolving microneedle array patches containing mesoporous silica nanoparticles of different pore sizes as a tunable sustained release platform

September 2023 in “bioRxiv (Cold Spring Harbor Laboratory)”

Microneedle patches with different pore sizes can effectively deliver drugs and trigger strong immune responses.

research The Increasing Importance of the Hair Follicle Route in Dermal and Transdermal Drug Delivery

9 citations , January 2015 in “Springer eBooks”

Using hair follicles can improve skin drug delivery.

View more "sustained drug release" in research →

Community Join

5 / 198 results

community Breezula Phase III 12-Month Data Released by Cosmo Pharma

in Research/Science 39 upvotes 3 months ago

Clascoterone 5% topical solution is effective and safe for long-term use in treating male pattern hair loss. Cosmo Pharma aims for EU and US approval, with a potential US release in late 2027 or early 2028.

community Does Finasteride Sustain Minoxidil-grown Hairs?

in Finasteride/Dutasteride 8 upvotes 2 years ago

The post discusses whether finasteride can maintain hair growth stimulated by minoxidil. The response indicates that finasteride cannot sustain minoxidil-grown hairs.

community People are hyped about PP405 but what about Veradermics phase 2!

in Research/Science 39 upvotes 9 months ago

Veradermics' phase 2 trial of slow-release oral minoxidil shows promising hair regrowth with minimized side effects, gaining significant attention and funding. PP405 is also noted for its potential as a side-effect-free alternative.

community Anageninc no longer sell KX-826 (Pyrilutamide) due to receiving a cease and desist letter from Kintor :(

in Update 19 upvotes 3 years ago

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. Anageninc stopped selling KX-826 (Pyrilutamide) due to a cease and desist letter from Kintor, but this may indicate promising study results and a potential 2024 release.

community [Theory] Big Bald is deliberately delaying the cure indefinitely

in Satire 343 upvotes 11 months ago

The conversation humorously suggests that the hair loss industry, referred to as "Big Bald," deliberately delays a cure to profit from ongoing treatments like minoxidil, finasteride, and dutasteride. Participants debate whether a cure would be more profitable than current treatments, with some suggesting that the industry prefers continuous treatments for sustained profit.

View more "sustained drug release" in community →